[go: up one dir, main page]

WO2019101709A1 - Oxadiazole derivatives for the treatment of genetic diseases due to nonsense mutations - Google Patents

Oxadiazole derivatives for the treatment of genetic diseases due to nonsense mutations Download PDF

Info

Publication number
WO2019101709A1
WO2019101709A1 PCT/EP2018/081850 EP2018081850W WO2019101709A1 WO 2019101709 A1 WO2019101709 A1 WO 2019101709A1 EP 2018081850 W EP2018081850 W EP 2018081850W WO 2019101709 A1 WO2019101709 A1 WO 2019101709A1
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
oxadiazol
compounds
cftr
nonsense
Prior art date
Application number
PCT/EP2018/081850
Other languages
French (fr)
Inventor
Ivana PIBIRI
Andrea PACE
Marco TUTONE
Laura LENTINI
Raffaella MELFI
Aldo DI LEONARDO
Original Assignee
Universita' Degli Studi Di Palermo
Fondazione Per La Ricerca Sulla Fibrosi Cistica - Onlus
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universita' Degli Studi Di Palermo, Fondazione Per La Ricerca Sulla Fibrosi Cistica - Onlus filed Critical Universita' Degli Studi Di Palermo
Priority to EP18807926.3A priority Critical patent/EP3713934B1/en
Priority to US16/770,240 priority patent/US11203578B2/en
Publication of WO2019101709A1 publication Critical patent/WO2019101709A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • the present invention refers to the pharmaceutical field since it relates to new oxadiazole derivatives for the treatment of diseases associated with the presence of a nonsense mutation in the gene or a premature stop codon in the mRNA.
  • nonsense mutations in the DNA generate premature termination codons (PTCs) in the mRNA, this class mutations interrupt the activity of a gene, making the product protein absent or not functional.
  • PTCs premature termination codons
  • Different types of nonsense mutations were observed in CF and are responsible for about lack adequate levels of the regulator CFTR, a chloride channel that is necessary for normal function of vital organs such as the lung, pancreas, liver ( Sermet-Gaudelus I, Boeck KD, Casimir GJ, Vermeulen F, Leal T, Mogenet A, Roussel D, Fritsch J, Hanssens L, Hirawat S, Miller NL, Constantine S, Reha A, Ajayi T, Elfring GL, Miller LL.
  • Ataluren induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis., Am J Respir Crit Care Med. 2010 Nov 15; 182 (10) : 1262-72) .
  • a potential treatment of this genetic alteration is to promote the readthrough of PTCs by the use of drugs with readthrough action (TRIDs) (S.M. Rowe, J.P. Clancy, Pharmaceuticals targeting nonsense mutations in genetic diseases, Biodrugs 23 (2009) 165-174)
  • TIDs drugs with readthrough action
  • Aminoglycosides antibiotics such as gentamicin, tobramycin, amikacin, were considered as potential treatment for conditions caused by nonsense mutations, to suppress the normal proofreading function of the ribosome, leading to insertion of a near-cognate amino acid at a PTC and translation of full-length protein (L.S. Me Coy, Y. Xie, Y. Tor, Antibiotics that target protein synthesis, Wiley Interdiscip. Rev. RNA 2 (2011) 209-232; V. Malik, L.R. Rodino- Klapac, L. Viollet, J.R.
  • aminoglycoside action lacks specificity resulting in readthrough of many correctly positioned stop codons.
  • a complication of long-term use of aminoglycosides is their nephrotoxicity and ototoxicity (A. Prayle, A.R. Smyth, Aminoglycoside use in cystic fibrosis: therapeutic strategies and toxicity, Curr. Opin. Pulm. Med. 16 (2010) 604-610) .
  • Ataluren a small molecule, that is used at lower dose with respect to aminoglycosides, inducing the readthrough of premature but not normal termination codons without the toxicity of aminoglycosides (E.M. Welch, E.R. Barton, J. Zhuo, Y. Tomizawa, W.J. Friesen, P. Trifillis, S. Paushkin, M. Patel, C.R. Trotta, S. Hwang, R.G. Wilde, G. Karp, J. Takasugi, G. Chen, S. Jones, H. Ren, Y.C. Moon, D. Corson, A.
  • Ataluren has a controversial preclinic and clinic history as some studies did not find evidence of its readthrough activity (Harmer, S. C.; Mohal, J. S.; Kemp, D.; Tinker, A., Readthrough of long-QT syndrome type 1 nonsense mutations rescues function but alters the biophysical properties of the channel. Biochem J 2012, 443 (3), 635-42; McElroy, S. P.; Nomura, T.; Torrie, L. S.; Warbrick, E.; Gartner, U.; Wood, G.; McLean, W. H., A lack of premature termination codon read- through efficacy of PTC124 (Ataluren) in a diverse array of reporter assays. PLoS Biol 2013, 11 (6), el001593) .
  • Stop codon read-through with PTC124 induces palmitoyl-protein thioesterase-1 activity, reduces thioester load and suppresses apoptosis in cultured cells from INCL patients. Mol Genet Metab 2011, 104 (3), 338- 45) .
  • Ataluren has passed Phase III clinical trials for DMD patients and is currently licensed in the European Economic Area for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) in ambulatory patients aged five years and older under the trade name TranslarnaTM (6th, March, 2017 PTC Therapeutics, Release Agency) .
  • nmDMD Duchenne muscular dystrophy
  • TranslarnaTM 6th, March, 2017 PTC Therapeutics, Release Agency
  • PTC Therapeutics closed ongoing extension studies and withdraw the application at FDA for marketing authorization in cystic fibrosis. (2nd, March, 2017 PTC Therapeutics, Release Agency) .
  • US patent application publication US2017/0204073 discloses compounds for nonsense suppression, and methods for their use.
  • the inventors of the present invention in view of the findings of the prior art, investigated on molecules able to act on the genetic defect that disrupts the normal course of protein production, by the gene with a nonsense mutation, and unexpectedly synthetized and characterized a new class of compounds able to readthrough premature termination codons which can be used for the treatment of diseases caused by nonsense mutations.
  • R1 is selected from the group consisting of: amide derivatives, ester derivatives
  • R2 is selected from the group consisting of: alkyl, aryl, perfluoroalkyl, polyfluoroaryl . for use in the treatment of diseases caused by nonsense mutations and pharmaceutical composition comprising a pharmacologically effective amount of at least one compound of formula (I) or its prodrug or mixture thereof and pharmaceutically acceptable excipients, for use in the treatment of diseases caused by UGA nonsense mutations.
  • Figure 1 shows in the left panel the test-set and in the right panel the training-set plots for Hypo .7.
  • Figure 2 shows a histogram showing luciferase (FLuc) activity after 24h of exposition to ATALUREN and its analogues in HeLa FLuc-opal transfected cells.
  • Figure 3 shows a colony PCR
  • Figure 4 shows a selective PCR.
  • Figure 5 shows in panel A the real time RT-PCR to visualize CFTR expression after Zeocin selection in FRT cells; in panel B the western blot analysis to detect CFTR protein in FRT transfected cells (CFTR wild type and nsCFTR(opal) . Beta- tubulin was used as control for the protein loading.
  • Figure 6 shows the cell viability test for our compounds compared to Ataluren.
  • Figure 7 shows the percentages of dead cells and proliferating cells after treatment with 12mM compounds and 12mM ataluren.
  • diseases caused by nonsense mutations means disease caused by a point mutation in the sequence of DNA resulting in a premature stop codon in the transcribed mRNA, and in a truncated, incomplete, and non functional protein product, wherein stop codons in RNA are UAG (amber), UAA (ochre) and UGA (opal) .
  • Nonsense mutation generates UGA, UAA and UAG premature termination codons.
  • the diseases caused by nonsense mutations can be CNS diseases, inflammatory diseases, neurodegenerative diseases, autoimmune diseases, cardiovascular diseases, pulmonary diseases. More specifically are cancer or other proliferative diseases, amyloidosis, Alzheimer's disease, atherosclerosis, giantism, dwarfism, hypothyroidism, hyperthyroidism, cystic fibrosis, aging, obesity, Parkinson's disease, Niemann Pick's disease, familial hypercholesterolemia, retinitis pigmentosa, Marfan syndrome, lysosomal storage disorders, muscular dystrophies, cystic fibrosis, hemophilia, or classical late infantile neuronal ceroid lipofuscinosis (LINCL) , Cystic Fibrosis (CF) , Duchenne Muscular Dystrophy (DMD) , atherosclerosis, Alzheimer' s disease, amyloidosis, retinitis pigmentosa, Usher's syndrome, ALS, multiple sclerosis.
  • CNS diseases CNS diseases
  • pro-drug means a compound that, after administration, is metabolized into a pharmacologically active compound.
  • pharmaceutically acceptable excipients means any chemical alongside the active ingredient of a medication, such as, and not limited to, long term stabilization agents, bulking agents, fillers, diluents, agents facilitating drug absorption, agents reducing viscosity, agents enhancing solubility, agents facilitating powder flowability or non-stick properties, agents aiding in vitro stability, agents preventing denaturation or aggregation, agents improving shelf life, depending also upon the route of administration and the dosage form, which can be selected by the person skilled in the art in view of his common general knowledge.
  • Object of the invention is 2, 3, 4, 5, 6-pentafluoro-N- (5- (perfluorophenyl ) -1, 2, 4-oxadiazol-3-yl) benzamide .
  • An other object of the present invention is the method of preparation of 2, 3, 4, 5, 6-pentafluoro-N- (5- (perfluorophenyl) - 1 , 2 , 4-oxadiazol-3-yl ) benzamide by acylation with perfluorobenzoyl chloride of amine 2 according to the following reaction
  • an equal amount of perfluorobenzoyl chloride and pyridine are added to the amine dissolved in toluene, until consumption of starting material, followed by removal of the solvent and addition of water to the residue, then the final product is obtained by further purification.
  • purification is performed by extraction with ethyl acetate and chromatographic separation on silica gel using mixtures of petroleum ether and ethyl acetate as eluent followed by crystallization.
  • An other object of the present invention is 2, 3, 4,5,6- pentafluoro-N- (5- (perfluorophenyl ) -1,2, 4-oxadiazol-3- yl)benzamide for use as a medicament.
  • An other object of the present invention is 2, 3, 4,5,6- pentafluoro-N- (5- (perfluorophenyl ) -1,2, 4-oxadiazol-3- yl)benzamide for use for the treatment of diseases caused by nonsense mutations.
  • An other object of the present invention is a pharmaceutical composition
  • a pharmaceutical composition comprising a pharmacologically effective amount of 2 , 3 , 4 , 5 , 6-pentafluoro-N- ( 5- (perfluorophenyl ) -1, 2, 4-oxadiazol-
  • An other object of the present invention is N- (5-methyl-l, 2, 4- oxadiazol-3-yl ) acetamide for use as a medicament.
  • An other object of the present invention is N- (5-methyl-l, 2, 4- oxadiazol-3-yl ) acetamide for use in the treatment of diseases caused by nonsense mutation.
  • An other object of the present invention is a pharmaceutical composition
  • a pharmaceutical composition comprising a pharmacologically effective amount of N- ( 5-methyl-l , 2 , 4-oxadiazol-3-yl ) acetamide or its prodrug and pharmaceutically acceptable excipients.
  • An other object of the present invention is compound of formula (I)
  • R1 is selected from the group consisting of : amide derivatives, ester derivatives
  • R2 is selected from the group consisting of: alkyl, perfluoroalkyl, aryl, polyfluoroaryl for use in the treatment of diseases caused by nonsense mutations .
  • R1 is amide derivative is selected from the group consisting of: alkyl amide, aryl amide, polyfluoroaryl amide.
  • R1 is ester derivative is polyfluoroaryl ester.
  • R1 is selected from the group consisting of:
  • R2 is alkyl is selected from the group consisting of: methyl, ethyl, propyl.
  • R2 is perfluoroalkyl is selected from the group consisting of: perfluoromethyl , perfluoropropy1 , perfluoroheptyl .
  • R2 is aryl is phenyl. More preferably R2 is selected from the group consisting of:
  • composition comprising a pharmacologically effective amount of at least one compound of formula (I) or its prodrug or mixture thereof and pharmaceutically acceptable excipients, for use in the treatment of diseases caused by nonsense mutations.
  • Another object of the present invention is the method of preparation of ethyl 5-phenyl-l , 2 , 4-oxadiazole-3-carboxylate by amidoxime route according to the following reaction
  • amidoxime 1 was dissolved in toluene, then equal amount of aroyl chloride and pyridine were added until consumption of starting material, followed by removal of the solvent and addition of water to the residue, then the final product is obtained by further purification.
  • Preferably purification is performed by extraction with ethyl acetate and chromatographic separation on silica gel using mixtures of petroleum ether and ethyl acetate as eluent allowed to obtain the desired oxadiazole and further purification by crystallization.
  • the disease caused by nonsense mutations is selected from the group consisting of: CNS diseases, inflammatory diseases, neurodegenerative diseases, autoimmune diseases, cardiovascular diseases, pulmonary diseases, proliferative diseases.
  • the disease caused by nonsense mutations is selected from the group consisting of cancer, amyloidosis, Alzheimer's disease, atherosclerosis, giantism, dwarfism, hypothyroidism, hyperthyroidism, cystic fibrosis, aging, obesity, Parkinson's disease, Niemann Pick's disease, familial hypercholesterolemia, retinitis pigmentosa, Marfan syndrome, lysosomal storage disorders, muscular dystrophies, cystic fibrosis, hemophilia, or classical late infantile neuronal ceroid lipofuscinosis (LINCL) , Cystic Fibrosis (CF) , Duchenne Muscular Dystrophy (DMD) , atherosclerosis, Alzheimer' s disease, amyloidosis, retinitis pigmentosa, Usher' s syndrome, ALS, multiple sclerosis.
  • cancer amyloidosis
  • Alzheimer's disease atherosclerosis
  • giantism dwarfism
  • hypothyroidism hypo
  • the disease caused by UGA nonsense mutations is Cystic Fibrosis (CF) , Duchenne Muscular Dystrophy (DMD ) .
  • the tests were focused in particular on CFTR as a model, due to the lack of therapy and the wide diffusion of this genetic disease .
  • IKK-b inhibitors An analysis of drug-receptor interaction by using Molecular Docking and Pharmacophore 3D- QSAR approaches (2010) Journal of Molecular Graphics and Modelling, 29 (1), pp . 72-81; Almerico, A.M., Tutone, M., Lauria, A. Receptor-guided 3D-QSAR approach for the discovery of c-kit tyrosine kinase inhibitors (2012) Journal of Molecular Modeling, 18 (7), pp . 2885-2895; Almerico, A.M., Tutone, M. , Pantano, L., Lauria, A.
  • A3 adenosine receptor Homology modeling and 3D-QSAR studies (2013) Journal of Molecular Graphics and Modelling, 42, pp. 60-72; Perricone, U., Wieder, M., Seidel, T., Langer, T., Padova, A., Almerico, A.M., Tutone, M. A Molecular Dynamics-Shared Pharmacophore Approach to Boost Early-Enrichment Virtual Screening: A Case Study on Peroxisome Proliferator-Activated Receptora (2017 ) ChemMedChem, 2017, 12, 1399-1407; Pibiri, I., Lentini, L.,
  • Models generated were measured according appropriate measures of goodness-of-fit, robustness, and predictive capability.
  • yiyi are the actual and predicted activities of the ith molecule, respectively, and y is the average activity of all molecules .
  • Predictive capability of the models generated was assessed by means of the external validation of the test set. Used statistics for external validation are: Q2ext (eq.2), Golbraikh and Tropsha parameters R20 e R' 20 , and and k' [29], r2m metrics >0.65,
  • y j yJ are the actual and predicted activities of the ith molecule, respectively, y tr is the average activity of all molecules in the training set .
  • HRMS spectra were recorded by analysing a 50 ppm solution of the compound in a 6540 UHD Accurate-Mass Q-TOF LC/MS (Agilent Technologies) equipped with a Dual AJS ESI source.
  • GC-MS spectra have been registered by using either an Agilent 7890B/7000C GC-MS-TQ or a GC-MS Shimadzu QP-2010 Instrument. Flash chromatography was performed by using silica gel (Merck, 0.040-0.063 mm) and mixtures of ethyl acetate and petroleum ether (fraction boiling in the range of 40-60 °C) in various ratios.
  • the QikProp program (QikProp, version 4.4, Schrodinger, LLC, New York, NY, 2015) was used to obtain the ADME properties of our compounds, and ATALUREN. It predicts both physically significant descriptors and pharmaceutically relevant features, such as principal descriptors and physiochemical properties. It also evaluated the drug-like acceptability of the compounds, based on Lipinski's rule of five, essential for rational drug design.
  • NV848 3-acetylamino-5- methyl-1 , 2 , 4-oxadiazole
  • N. Vivona, M. Ruccia, G. Cusmano, M. L. Marino, D. Spinelli The thermally degenerate mononuclear rearrangement of 3- acetylamino-5-methyl-l , 2 , 4-oxadiazole, J . Heterocycl . Chem. 1975, 12, 1327-1328; A. Mugnoli, G. Barone, S. Buscemi,C. Z.
  • NV930 has been prepared by the classic amidoxime route: The amidoxime 1 (0.3 g) (prepared as reported in (P. S. Branco, S. Prabhakar, A. M. Lobo, D. J. Williams, "Reactions of hydroxylamines with ethyl cyanoformate . preparation of aminonitrones and their synthetic applications . "tetrahedron 1992, 48, 6335-6360)) was dissolved in 50 mL of toluene in a 250 mL round bottomed flask. Then, 1.2 eq. of the appropriate aroyl chloride and 1.2 eq.
  • NV914 has been prepared by acylation with perfluorobenzoyl chloride of the amine 2, the latter reported in (Buscemi, Silvestre; Pace, Andrea; Pibiri, Ivana; Vivona, Nicolo; Caronna, Tullio, "Fluorinated heterocyclic compounds: an assay on the photochemistry of some fluorinated l-oxa-2-azoles : an expedient route to fluorinated heterocycles" Journal of
  • the FLuc cell-based assay To ascertain the effectiveness of the newly synthesized ataluren analogues in promoting the readthrough of premature termination codons was used the FLuc cell-based assay.
  • HeLa cells were transfected transiently with the plasmids pFLuc-wild type (control) and pFLuc-opal (UGA stop mutation) (NIH Chemical Genomics Center, National Institutes of Health, Bethesda, USA) . FLuc gene expression was then measured by luminescence. HeLa cells transfected with the pFluc-wild type plasmid showed high levels of luciferase activity confirming the functioning of the assay.
  • pFluc-opal cells did not show any activity but, after 24 hours from transfection, they were treated, for additional 24 hours, with ataluren and 58 different ataluren analogues all at the same concentration of 12mM. Following treatment a significant increase of luciferase activity, if compared to untreated, with: NV848, NV914, NV930 was observed as shown in figure 2.
  • the G542X, FRT cells were engineered with a vector expressing nsCFTR (nonsense) .
  • thermostable DNA polymerase lacking 3' to 5' proofreading activity (DyNAzymeTM II DNA Polymerase) , identical amount of purified plasmid DNA, either wild type or mutagenized, and the reverse primer SEQ. ID. NO. 3: 5' ctaatgagaaacggtgtaag 3' CFTRup2.
  • a DNA fragment of the correct size was amplified where expected, either in clone-1 or wild type DNA and in positive controls, as shown in figure4.
  • FRT cells were transfected with the pTRACER vectors containing either the wild type CFTR or the nsCFTR (G542X-opal) cDNA and selected by Zeocin resistance.
  • the advantage of the use of these cells is that they don't express cAMP dependent channels (as CFTR) or CFTR protein.
  • the expression of the human CFTR wild type and nsCFTR (G542X-opal ) in transfected FRT cells was evaluated by qRT-PCR and Western blot, as shown in figure 5.
  • HeLa cells were used to determine the possible cytotoxic effects of our compounds and the impact on cell proliferation.
  • figure 7 are reported the percentages of dead cells and proliferating cells after treatment with 12mM compounds and 12mM ATALUREN.
  • the results showed that the compounds and ATALUREN induce alight increase in dead cells at 24h (ATALUREN: 4%; NV848:7; NV914: 5; NV930 : 2) and 72h (ATALUREN: 7%; NV848:6; NV914: 2; NV930 : 4 that was constant in the time.
  • ATALUREN 4%; NV848:7; NV914: 5; NV930 : 2
  • 72h ATALUREN: 7%; NV848:6; NV914: 2; NV930 : 4 that was constant in the time.
  • Istars Number of property or descriptor values that fall outside the 95% range of similar values for known drugs large number of stars suggests that a molecule is less drug like than molecules with few stars.
  • the following properties and descriptors are included in the determination of Istars: MW, dipole, IP, EA, SASA, FOSA, FISA, PISA, WPSA, PSA, volume, #rotor, donorHB, accptHB, glob, QPpolrz, QPlogPC16, QPlogPoct, QPlogPw, QPlogPo/w, logS , QPLogKhsa, QPlogBB, #metabol, as shown in the following Table 4 wherein all the calculated values for the compounds were compared with the calculated values for ataluren. Table 4
  • SASA Total solvent accessible surface area in square angstroms using a probe with a 1.4 A radius
  • FOSA Hydrophobic component of the SASA (saturated carbon and attached hydrogen)
  • FISA Hydrophilic component of the SASA (SASA on N, 0, H on 10 heteroatoms, carbonyl C)
  • PISA Hydrophilic component of the SASA
  • WPSA Weakly polar component of the SASA (halogens, P, and S)
  • Volume Total solvent- accessible volume in cubic angstroms using a probe with a 1.4 A radius
  • #rotor number of rotatable bonds
  • donorHB number 15 of h-bond donor, accptHB, number of H-bond acceptor
  • glob
  • Globularity descriptor, (4nr2) v (SASA) where r is the radius of a sphere with a volume equal to the molecular volume; QPpolrz, Predicted polarizability in cubic angstroms, QPlogPC16, Predicted hexadecane/gas partition coefficient; QPlogPoct, Predicted octanol/gas partition coefficient ;
  • QPlogPw Predicted water/gas partition coefficient
  • QPlogPo/w Predicted octanol/water partition coefficient.
  • QPlogKhsa Prediction of binding to human serum albumin
  • QPlogBB Predicted brain/blood partition coefficient
  • #metab Number of likely metabolic reactions.
  • the compounds respect the Lipinski's rule of five, and they have a predicted human oral absorption between 70 and 100%.
  • nsCFTR nonsense-CFTR
  • CFTR protein was revealed by a specific antibody targeting its first external portion and a secondary antibody (SC2092-red) . Nuclei (blue) were DAPI stained.
  • a quench- EYFP assay was performed. This assay is based on iodide- mediated quenching rates of an ectopically expressed mutant form of the Yellow fluorescent protein (YFP) .
  • YFP Yellow fluorescent protein
  • nsCFTR (G542X-opal ) FRT-cells were transfected with the plasmid pCDNA3.1 EYFP (M148Q; I152L) and selected for the resistance to the G418 antibiotic.
  • Cells were plated in a 6 well plate one day before the experiment, they were stimulated with forskolin (20 mM) for 20 min and placed in a buffer containing iodide (PBSlx similar buffer, NaCl is replaced by equimolars of Nal) . Changes in fluorescence intensity were monitored by a Zeiss fluorescence microscope and the images were recorded every 1.5 s with a CCD digital camera (AxioCam, Zeiss) . The same analysis was performed by measuring the changes in fluorescence intensity by a fluorimeter confirming the activity of the CFTR channel in these cells.
  • PBSlx similar buffer, NaCl is replaced by equimolars of Nal
  • FRT cells were also engineered with a vector expressing nsCFTR (nonsense) .
  • nsCFTR nonsense
  • Site 15 Directed Mutagenesis of the full-length CFTR cDNA cloned in the pTracer Zeocin (pTCF-wild type) vector was performed, the CFTR DNA is available at NCBI Reference Sequence NG_016465.4.
  • Dpnl restriction enzyme target: 5'Gm6ATC3 '
  • Newly synthesized plasmids were transformed into XLl-Blue competent cells. We obtained 11 colonies from Q552X reaction and 12 from R553X. All were confirmed to bring the pTracer- CFTR plasmid by colony PCR, performed with two primers perfectly annealing to the template at 56°C:
  • Q552X clone 1 and R553X clone 18 were selected for further characterization by selective PCR, based on the use of the CFTRup2 reverse primer SEQ.ID No. 9 paired with the following selective forward primers : cl654tdw for Q552X SEQ.ID No. 12 aatcacactgagtggaggtt or cl657tdw for R553X SEQ.ID No. 13 cacactgagtggaggtcaat
  • mutant clones 1 and 18 were used. Amplification efficiency, of mutant clones 1 and 18 was the same at any annealing T (Ta) while in the case of wt template DNA, it decreased as the Ta raised (380 bp amplicon became almost undetectable at 56°C) . This suggested that both clones were positive to mutagenesis. A DNA fragment of 608bp was amplified in positive controls, as expected. Successful mutagenesis was confirmed by sequencing (BRM genomics) :
  • NV914 and NV930 FRT cells were transfected with the pTracer vectors containing either the WT-CFTR (CFTRWT ) or the R553X-CFTR and the Q552X- CFTR (nsCFTR- R553X-opal, nsCFTR-Q552X ochre) human cDNA and selected by Zeocin resistance.
  • the expression of the CFTRWT and nsCFTR CFTR (nsCFTR- R553X-opal, nsCFTR-Q552X ochre) in transfected FRT cells was evaluated by qRT-PCR.
  • nsCFTR- Q552X ochre, nsCFTR- R553X-opal FRT transfected cells were treated with NV848, (12mM) , and ATALUREN (12 m M) as positive control, for 24 hours and the expression of the human CFTR was evaluated by immunofluorescence analysis. Immunofluorescence microscopy images showed that the exposition of the nsCFTR- R553X-opal, nsCFTR-Q552X ochre FRT cells to the NV848, NV914, NV930 compounds induced the CFTR full-length expression and membrane localization.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Are disclosed oxadiazole derivatives, their use as medicaments and in particular for the treatment of diseases associated with the presence of a nonsense mutation in the gene or a premature stop codon in the mRNA, pharmaceutical formulation comprising said oxadiazole derivatives and prodrug or mixture thereof and the methods for the preparation of said Oxadiazole derivatives.

Description

Oxadiazole derivatives for the treatment of genetic diseases due to nonsense mutations
*****
Background of the invention The present invention refers to the pharmaceutical field since it relates to new oxadiazole derivatives for the treatment of diseases associated with the presence of a nonsense mutation in the gene or a premature stop codon in the mRNA.
State of the art Several cases of Mendelian genetic diseases are due to the presence of nonsense mutations in the DNA generating premature PTCs in the mRNA, able to interrupt the activity of a gene, making the product protein absent or not functional. This serious lack of functional protein is reflected in the establishment of a pathological condition in life Diseases such as Cystic Fibrosis (CF) and Duchenne Muscular Dystrophy (DMD) , for the percentage related to nonsense mutations (J.T. Mendell, H.C. Diez, When the message goes awry: disease- producing mutations that influence mRNA content and performance, Cell 107 (2001) 411-414; L. Bidou, V. Allamand,
J.P. Rousset, 0. Namy, Sense from nonsense: therapies for premature stop codon diseases, Trends Mol. Med. 18 (2012) 679-
688; T. Goldmann, N. Overlack, F. Moller, V. Belakhov, M. van
Wyk, T. Baasov, U. Wolfrum, K. Nagel-Wolfrum, A comparative evaluation of NB30, NB54 and PTC124 in translational read- through efficacy for treatment of an USH1C nonsense mutation, EMBO Mol. Med. 4 (2012) 1186-1199).
The presence of nonsense mutations in the DNA generate premature termination codons (PTCs) in the mRNA, this class mutations interrupt the activity of a gene, making the product protein absent or not functional. Different types of nonsense mutations were observed in CF and are responsible for about
Figure imgf000002_0001
lack adequate levels of the regulator CFTR, a chloride channel that is necessary for normal function of vital organs such as the lung, pancreas, liver ( Sermet-Gaudelus I, Boeck KD, Casimir GJ, Vermeulen F, Leal T, Mogenet A, Roussel D, Fritsch J, Hanssens L, Hirawat S, Miller NL, Constantine S, Reha A, Ajayi T, Elfring GL, Miller LL. Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis., Am J Respir Crit Care Med. 2010 Nov 15; 182 (10) : 1262-72) .
A potential treatment of this genetic alteration is to promote the readthrough of PTCs by the use of drugs with readthrough action (TRIDs) (S.M. Rowe, J.P. Clancy, Pharmaceuticals targeting nonsense mutations in genetic diseases, Biodrugs 23 (2009) 165-174)
Aminoglycosides antibiotics, such as gentamicin, tobramycin, amikacin, were considered as potential treatment for conditions caused by nonsense mutations, to suppress the normal proofreading function of the ribosome, leading to insertion of a near-cognate amino acid at a PTC and translation of full-length protein (L.S. Me Coy, Y. Xie, Y. Tor, Antibiotics that target protein synthesis, Wiley Interdiscip. Rev. RNA 2 (2011) 209-232; V. Malik, L.R. Rodino- Klapac, L. Viollet, J.R. Mendell, Aminoglycoside-induced mutation suppression (stop codon read- through) as a therapeutic strategy for Duchenne muscular dystrophy, Ther. Adv. Neurol. Disord. 3 (2010) 379-389; J. Karijolich, Y.T. Yu, Therapeutic suppression of premature termination codons: mechanisms and clinical considerations (Review), Int. J. Mol. Med. 34 (2014) 355-362) .
Unfortunately, aminoglycoside action lacks specificity resulting in readthrough of many correctly positioned stop codons. Moreover, a complication of long-term use of aminoglycosides is their nephrotoxicity and ototoxicity (A. Prayle, A.R. Smyth, Aminoglycoside use in cystic fibrosis: therapeutic strategies and toxicity, Curr. Opin. Pulm. Med. 16 (2010) 604-610) .
At now, the lead product candidate for the treatment of patients with genetic disorders that arise from a nonsense mutation is Ataluren, a small molecule, that is used at lower dose with respect to aminoglycosides, inducing the readthrough of premature but not normal termination codons without the toxicity of aminoglycosides (E.M. Welch, E.R. Barton, J. Zhuo, Y. Tomizawa, W.J. Friesen, P. Trifillis, S. Paushkin, M. Patel, C.R. Trotta, S. Hwang, R.G. Wilde, G. Karp, J. Takasugi, G. Chen, S. Jones, H. Ren, Y.C. Moon, D. Corson, A. A. Turpoff, J.A. Campbell, M.M. Conn, A. Khan, N.G. Almstead, J. Hedrick, A. Mollin, N. Risher, M. Weetall, S. Yeh, A. A. Branstrom, J.M. Colacino, J. Babiak, W.D. Ju, S. Hirawat, V.J. Northcutt, L.L. Miller, P. Spatrick, F. He, M. Kawana, H. Feng, A. Jacobson, S.W. Peltz, H.L. Sweeney, PTC124 targets genetic disorders caused by nonsense mutations, Nature 447 (2007) 87-91; Kerem E, Hirawat S, Armoni S, Yaakov Y,
Shoseyov D, Cohen M, Nissim-Rafinia M, Blau H, Rivlin J,
Aviram M, Elfring GL, Northcutt VJ, Miller LL, Kerem B,
Wilschanski M., Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial., Lancet. 2008 Aug 30; 372 (9640) : 719-27; Sermet-Gaudelus I, Boeck KD, Casimir GJ, Vermeulen F, Leal T, Mogenet A, Roussel D, Fritsch J, Hanssens L, Hirawat S, Miller NL, Constantine S, Reha A, Ajayi T, Elfring GL, Miller LL . Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis., Am J RespirCrit Care Med. 2010 Nov 15; 182(10) :1262-72) .
Ataluren has a controversial preclinic and clinic history as some studies did not find evidence of its readthrough activity (Harmer, S. C.; Mohal, J. S.; Kemp, D.; Tinker, A., Readthrough of long-QT syndrome type 1 nonsense mutations rescues function but alters the biophysical properties of the channel. Biochem J 2012, 443 (3), 635-42; McElroy, S. P.; Nomura, T.; Torrie, L. S.; Warbrick, E.; Gartner, U.; Wood, G.; McLean, W. H., A lack of premature termination codon read- through efficacy of PTC124 (Ataluren) in a diverse array of reporter assays. PLoS Biol 2013, 11 (6), el001593) .
Other studies indicated an effective readthrough activity (Goldmann, T.; Overlack, N.; Moller, F.; Belakhov, V.; van Wyk, M.; Baasov, T.; Wolfrum, U.; Nagel-Wolfrum, K., A comparative evaluation of NB30, NB54 and PTC124 in translational read-through efficacy for treatment of an USH1C nonsense mutation. EMBO Mol Med 2012, 4 ( 11 ) , 1186-99; Sarkar, C.; Zhang, Z.; Mukherjee, A. B., Stop codon read-through with PTC124 induces palmitoyl-protein thioesterase-1 activity, reduces thioester load and suppresses apoptosis in cultured cells from INCL patients. Mol Genet Metab 2011, 104 (3), 338- 45) .
Ataluren has passed Phase III clinical trials for DMD patients and is currently licensed in the European Economic Area for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) in ambulatory patients aged five years and older under the trade name Translarna™ (6th, March, 2017 PTC Therapeutics, Release Agency) . Currently Ataluren is the first oral therapy to intervene on the molecular mechanisms involved in gene reading and translation into proteins. On the contrary, Phase III clinical trials for CF patients has been suspended because the results, unless positive, were considered not statistically significant. Recently, PTC Therapeutics closed ongoing extension studies and withdraw the application at FDA for marketing authorization in cystic fibrosis. (2nd, March, 2017 PTC Therapeutics, Release Agency) .
The same inventors of the present invention, suggested that it may be an interaction between the mRNA containing the UGA nonsense mutation and Ataluren as a mechanism of readthrough (L. Lentini, R. Melfi, A. Di Leonardo, A. Spinello, G. Barone, A. Pace, A. Palumbo Piccionello, I. Pibiri, Towards a rationale for the PTC124 (Ataluren) promoted read-through of premature stop codons: a computational approach and GFP reporter cell-based assay, Mol. Pharm. 11 (2014) 653-664; I. Pibiri, L. Lentini, R. Melfi, G. Gallucci, A. Pace, A. Spinello, G. Barone, A. Di Leonardo, Enhancement of premature stop codon readthrough in the CFTR gene by Ataluren (PTC124) derivatives, Eur. J. Med. Chem. 101 (2015) 236-244) .
Therefore, the same inventors of the present invention, in the attempt to shed light on these controversial results as well to get a better knowledge of the mechanism of action of small molecules as Ataluren, already designed and synthesized analogues of Ataluren to be tested in human cultured cells (I. Pibiri, L. Lentini, R. Melfi, G. Gallucci, A. Pace, A. Spinello, G. Barone, A. Di Leonardo, Enhancement of premature stop codon readthrough in the CFTR gene by Ataluren (PTC124) derivatives, Eur. J. Med. Chem. 101 (2015) 236-244; Pibiri I., Lentini L., Tutone M., Melfi R., Pace A., Di Leonardo A. Exploring the readthrough of nonsense mutations by non-acidic Ataluren analogues selected by ligand-based virtual screening, Eur. J. Med. Chem. 122 (2016) 429-435) .
International patent applications W02006044682, W02006044505, W02006044503, W02006044502 and W02006044456 discloses heterocyclic compounds for treating diseases associated with nonsense mutations in a mRNA and more in particular, International patent application W02006/044456 discloses 1 , 2 , 4 , -oxadiazole derivatives for the treatment of nonsense mutations .
International patent applications W02006110483 and W02008045566 disclose Ataluren for treating diseases associated with nonsense mutations.
International patent application W02008130370 discloses 1,2,4, oxadiazoles benzoic acid compounds for the modulation of premature translation or nonsense mRNA decay. International patent application W02011072281 discloses 1,2,4, oxadiazoles benzoic acid compounds for treating methylmalonic acidemia .
International patent application WO2015134711 discloses 1,2,4, oxadiazoles benzoic acid compounds for the treatment of diseases associated with nonsense mutation or premature codon stop .
International patent application WO2015188037 discloses 1,2,4, oxadiazoles benzoic acid compounds for the treatment of mucopolysaccharidosis .
US patent application publication US2017/0204073 discloses compounds for nonsense suppression, and methods for their use.
International patent application W02014/085490 and publication Senger J. et al . , 2015, J. Med. Chem, "Synthesys and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors", 59(4), 1545-1555 disclose the preparation of 5-phenyl-l , 2 , 4- oxadiazole-3-carboxylate by a two step synthesis wherein an open intermediate is first formed in DCM, isolated and then cyclized by heating in the presence of a base.
Technical problem
The compound known in the art, used to readthrough premature termination codons (PTCs) caused by nonsense mutations, present several drawbacks. As previously discussed, aminoglycosides known in the art present several drawbacks: lack of specificity and may readthrough not-mutated stop codons; in long-term treatment cause nephrotoxicity and ototoxicity; known experimental results on ataluren cytotoxicity are conflicting, ataluren has low bioavailability and when it restores readthrough of mutated stop codons the protein production is lower than in wild types. It is self evident that there is a long felt need for new readthrough promoters which can be efficiently used for the treatment of genetic diseases caused by mutations in stop codons . The inventors of the present invention, in view of the findings of the prior art, investigated on molecules able to act on the genetic defect that disrupts the normal course of protein production, by the gene with a nonsense mutation, and unexpectedly synthetized and characterized a new class of compounds able to readthrough premature termination codons which can be used for the treatment of diseases caused by nonsense mutations.
Object of the invention
Therefore, with reference to the attached claims and the following detailed description, the above technical problem is solved by the compound 2, 3, 4, 5, 6-pentafluoro-N- (5- (perfluorophenyl) -1, 2, 4-oxadiazol-3-yl) benzamide, its method of preparation, its use as a medicament, its use for the treatment of diseases caused by nonsense mutation and pharmaceutical composition comprising a pharmacologically effective amount of 2 , 3 , 4 , 5 , 6-pentafluoro-N- ( 5-
(perfluorophenyl ) -1 , 2 , 4-oxadiazol-3-yl ) benzamide or its prodrug and pharmaceutically acceptable excipients.
Compound N- (5-methyl-l, 2, 4-oxadiazol-3-yl) acetamide for use as a medicament and for use in the treatment of diseases caused by nonsense mutation and pharmaceutical composition comprising a pharmacologically effective amount of N- (5-methyl-l , 2 , 4- oxadiazol-3-yl ) acetamide or its prodrug and pharmaceutically acceptable excipients. Compounds of formula (I)
Figure imgf000008_0001
Wherein
R1 is selected from the group consisting of: amide derivatives, ester derivatives
R2 is selected from the group consisting of: alkyl, aryl, perfluoroalkyl, polyfluoroaryl . for use in the treatment of diseases caused by nonsense mutations and pharmaceutical composition comprising a pharmacologically effective amount of at least one compound of formula (I) or its prodrug or mixture thereof and pharmaceutically acceptable excipients, for use in the treatment of diseases caused by UGA nonsense mutations.
Brief Description of the Drawings
Figure 1 shows in the left panel the test-set and in the right panel the training-set plots for Hypo .7.
Figure 2 shows a histogram showing luciferase (FLuc) activity after 24h of exposition to ATALUREN and its analogues in HeLa FLuc-opal transfected cells.
Figure 3 shows a colony PCR.
Figure 4 shows a selective PCR.
Figure 5 shows in panel A the real time RT-PCR to visualize CFTR expression after Zeocin selection in FRT cells; in panel B the western blot analysis to detect CFTR protein in FRT transfected cells (CFTR wild type and nsCFTR(opal) . Beta- tubulin was used as control for the protein loading.
Figure 6 shows the cell viability test for our compounds compared to Ataluren.
Figure 7 shows the percentages of dead cells and proliferating cells after treatment with 12mM compounds and 12mM ataluren. Detailed Description of the Invention
Definitions
Within the meaning of the present invention diseases caused by nonsense mutations means disease caused by a point mutation in the sequence of DNA resulting in a premature stop codon in the transcribed mRNA, and in a truncated, incomplete, and non functional protein product, wherein stop codons in RNA are UAG (amber), UAA (ochre) and UGA (opal) . Nonsense mutation generates UGA, UAA and UAG premature termination codons.
The diseases caused by nonsense mutations can be CNS diseases, inflammatory diseases, neurodegenerative diseases, autoimmune diseases, cardiovascular diseases, pulmonary diseases. More specifically are cancer or other proliferative diseases, amyloidosis, Alzheimer's disease, atherosclerosis, giantism, dwarfism, hypothyroidism, hyperthyroidism, cystic fibrosis, aging, obesity, Parkinson's disease, Niemann Pick's disease, familial hypercholesterolemia, retinitis pigmentosa, Marfan syndrome, lysosomal storage disorders, muscular dystrophies, cystic fibrosis, hemophilia, or classical late infantile neuronal ceroid lipofuscinosis (LINCL) , Cystic Fibrosis (CF) , Duchenne Muscular Dystrophy (DMD) , atherosclerosis, Alzheimer' s disease, amyloidosis, retinitis pigmentosa, Usher's syndrome, ALS, multiple sclerosis.
Within the meaning of the present invention pro-drug means a compound that, after administration, is metabolized into a pharmacologically active compound.
Within the meaning of the present invention pharmaceutically acceptable excipients means any chemical alongside the active ingredient of a medication, such as, and not limited to, long term stabilization agents, bulking agents, fillers, diluents, agents facilitating drug absorption, agents reducing viscosity, agents enhancing solubility, agents facilitating powder flowability or non-stick properties, agents aiding in vitro stability, agents preventing denaturation or aggregation, agents improving shelf life, depending also upon the route of administration and the dosage form, which can be selected by the person skilled in the art in view of his common general knowledge. Object of the invention is 2, 3, 4, 5, 6-pentafluoro-N- (5- (perfluorophenyl ) -1, 2, 4-oxadiazol-3-yl) benzamide .
An other object of the present invention is the method of preparation of 2, 3, 4, 5, 6-pentafluoro-N- (5- (perfluorophenyl) - 1 , 2 , 4-oxadiazol-3-yl ) benzamide by acylation with perfluorobenzoyl chloride of amine 2 according to the following reaction
Figure imgf000011_0001
wherein an equal amount of perfluorobenzoyl chloride and pyridine are added to the amine dissolved in toluene, until consumption of starting material, followed by removal of the solvent and addition of water to the residue, then the final product is obtained by further purification. Preferably purification is performed by extraction with ethyl acetate and chromatographic separation on silica gel using mixtures of petroleum ether and ethyl acetate as eluent followed by crystallization. An other object of the present invention is 2, 3, 4,5,6- pentafluoro-N- (5- (perfluorophenyl ) -1,2, 4-oxadiazol-3- yl)benzamide for use as a medicament.
An other object of the present invention is 2, 3, 4,5,6- pentafluoro-N- (5- (perfluorophenyl ) -1,2, 4-oxadiazol-3- yl)benzamide for use for the treatment of diseases caused by nonsense mutations.
An other object of the present invention is a pharmaceutical composition comprising a pharmacologically effective amount of 2 , 3 , 4 , 5 , 6-pentafluoro-N- ( 5- (perfluorophenyl ) -1, 2, 4-oxadiazol-
3-yl ) benzamide or its prodrug and pharmaceutically acceptable excipients .
An other object of the present invention is N- (5-methyl-l, 2, 4- oxadiazol-3-yl ) acetamide for use as a medicament. An other object of the present invention is N- (5-methyl-l, 2, 4- oxadiazol-3-yl ) acetamide for use in the treatment of diseases caused by nonsense mutation.
An other object of the present invention is a pharmaceutical composition comprising a pharmacologically effective amount of N- ( 5-methyl-l , 2 , 4-oxadiazol-3-yl ) acetamide or its prodrug and pharmaceutically acceptable excipients.
An other object of the present invention is compound of formula (I)
Figure imgf000012_0001
Wherein R1 is selected from the group consisting of : amide derivatives, ester derivatives
R2 is selected from the group consisting of: alkyl, perfluoroalkyl, aryl, polyfluoroaryl for use in the treatment of diseases caused by nonsense mutations .
Preferably when R1 is amide derivative is selected from the group consisting of: alkyl amide, aryl amide, polyfluoroaryl amide. Preferably when R1 is ester derivative is polyfluoroaryl ester.
More preferably R1 is selected from the group consisting of:
Figure imgf000013_0001
Preferably when R2 is alkyl is selected from the group consisting of: methyl, ethyl, propyl. Preferably when R2 is perfluoroalkyl is selected from the group consisting of: perfluoromethyl , perfluoropropy1 , perfluoroheptyl .
Preferably when R2 is aryl is phenyl. More preferably R2 is selected from the group consisting of:
Figure imgf000014_0001
CH3
Figure imgf000014_0002
for use in the treatment of diseases caused by nonsense mutations and pharmaceutical. More preferably compounds of formula (I) are selected from the group consisting of:
2 , 3 , 4 , 5 , 6-pentafluoro-N- ( 5- (perfluorophenyl ) -1, 2, 4-oxadiazol- 3-yl ) benzamide
N- ( 5-methyl-l , 2, 4-oxadiazol-3-yl) acetamide ethyl 5-phenyl-l , 2 , 4-oxadiazole-3-carboxylate
An other object of the present invention are composition comprising a pharmacologically effective amount of at least one compound of formula (I) or its prodrug or mixture thereof and pharmaceutically acceptable excipients, for use in the treatment of diseases caused by nonsense mutations.
Another object of the present invention is the method of preparation of ethyl 5-phenyl-l , 2 , 4-oxadiazole-3-carboxylate by amidoxime route according to the following reaction
Figure imgf000015_0001
Wherein amidoxime 1 was dissolved in toluene, then equal amount of aroyl chloride and pyridine were added until consumption of starting material, followed by removal of the solvent and addition of water to the residue, then the final product is obtained by further purification.
Preferably purification is performed by extraction with ethyl acetate and chromatographic separation on silica gel using mixtures of petroleum ether and ethyl acetate as eluent allowed to obtain the desired oxadiazole and further purification by crystallization.
Preferably the disease caused by nonsense mutations is selected from the group consisting of: CNS diseases, inflammatory diseases, neurodegenerative diseases, autoimmune diseases, cardiovascular diseases, pulmonary diseases, proliferative diseases.
More preferably the disease caused by nonsense mutations is selected from the group consisting of cancer, amyloidosis, Alzheimer's disease, atherosclerosis, giantism, dwarfism, hypothyroidism, hyperthyroidism, cystic fibrosis, aging, obesity, Parkinson's disease, Niemann Pick's disease, familial hypercholesterolemia, retinitis pigmentosa, Marfan syndrome, lysosomal storage disorders, muscular dystrophies, cystic fibrosis, hemophilia, or classical late infantile neuronal ceroid lipofuscinosis (LINCL) , Cystic Fibrosis (CF) , Duchenne Muscular Dystrophy (DMD) , atherosclerosis, Alzheimer' s disease, amyloidosis, retinitis pigmentosa, Usher' s syndrome, ALS, multiple sclerosis.
Even more preferably the disease caused by UGA nonsense mutations is Cystic Fibrosis (CF) , Duchenne Muscular Dystrophy (DMD ) .
Examples
58 molecules have been synthetized, some of them identified by a virtual screening, and evaluate their activity by using different assays: the F-Luc assay using a vector containing a UGA in the cDNA of the F-Luc and epithelial rat cells transfected with a CFTR nonsense mutated cDNA.
The tests were focused in particular on CFTR as a model, due to the lack of therapy and the wide diffusion of this genetic disease .
Example 1 Virtual Design and Synthesis
Concerning the 3D-QSAR pharmacophore modelling, used processing procedures for the structures and models generation were as disclosed in [Almerico, A.M., Tutone, M. , Lauria, A. 3D-QSAR pharmacophore modeling and in silico screening of new Bcl-xl inhibitors (2010) European Journal of Medicinal Chemistry, 45 (11), pp. 4774-4782; Lauria, A., Ippolito, M., Fazzari, M. , Tutone, M. , Di Blasi, F., Mingoia, F., Almerico, A.M. IKK-b inhibitors: An analysis of drug-receptor interaction by using Molecular Docking and Pharmacophore 3D- QSAR approaches (2010) Journal of Molecular Graphics and Modelling, 29 (1), pp . 72-81; Almerico, A.M., Tutone, M., Lauria, A. Receptor-guided 3D-QSAR approach for the discovery of c-kit tyrosine kinase inhibitors (2012) Journal of Molecular Modeling, 18 (7), pp . 2885-2895; Almerico, A.M., Tutone, M. , Pantano, L., Lauria, A. A3 adenosine receptor: Homology modeling and 3D-QSAR studies (2013) Journal of Molecular Graphics and Modelling, 42, pp. 60-72; Perricone, U., Wieder, M., Seidel, T., Langer, T., Padova, A., Almerico, A.M., Tutone, M. A Molecular Dynamics-Shared Pharmacophore Approach to Boost Early-Enrichment Virtual Screening: A Case Study on Peroxisome Proliferator-Activated Receptora (2017 ) ChemMedChem, 2017, 12, 1399-1407; Pibiri, I., Lentini, L.,
Tutone, M. , Melfi, R. , Pace, A., Di Leonardo, A. Exploring the readthrough of nonsense mutations by non-acidic Ataluren analogues selected by ligand-based virtual screening (2016) European Journal of Medicinal Chemistry, 122, pp . 429-435;
Tutone, M. , Pantano, L., Lauria, A., Almerico, A.M. Molecular dynamics, dynamic site mapping, and highthroughput virtual screening on leptin and the Ob receptor as anti-obesity target (2014) Journal of Molecular Modeling, 20 (5), Phase, version
4.3, Schrodinger, LLC, New York, NY, 2015. Dixon, S. L.;
Smondyrev, A. M.; Knoll, E. H.; Rao, S. N.; Shaw, D. E.;
Friesner, R. A., "PHASE: A New Engine for Pharmacophore Perception, 3D QSAR Model Development, and 3D Database Screening. 1. Methodology and Preliminary Results," J. Comput . Aided Mol. Des. , 2006, 20, 647-671. and Phase software was
Phase, version 4.3, Schrodinger, LLC, New York, NY, 2015.
Models generated were measured according appropriate measures of goodness-of-fit, robustness, and predictive capability.
Used statistics for goodness-of fit are: R2, SD (standard deviation), F (Fisher test), p value, RMSE (rootmean square error) , Pearson-R. Used statistics to measure robustness of the model are: Q2(eq.l)
Figure imgf000017_0001
Eq.1
Where yiyi are the actual and predicted activities of the ith molecule, respectively, and y is the average activity of all molecules .
Predictive capability of the models generated was assessed by means of the external validation of the test set. Used statistics for external validation are: Q2ext (eq.2), Golbraikh and Tropsha parameters R20 e R' 20 , and and k' [29], r2m metrics >0.65,
Figure imgf000018_0001
Eq.2
Where yjyJ are the actual and predicted activities of the ith molecule, respectively, ytr is the average activity of all molecules in the training set .
All solvents and reagents were commercially available. All synthesized compounds were purified by chromatography and analysed by IR, HRMS, GC-MS, and NMR. Purity of synthesized compounds was verified prior to biological tests by chromatographic analyses and NMR (see supplementary material) and in all the cases purity was higher than 95%. IR spectra have been registered with a Shimadzu FTIR-8300 spectrophotometer; melting points have been determined on a Reichart-Thermovar hotstage Kofler and are uncorrected. NMR spectra have been registered on a Bruker AVANCE DMX 300 using CDC13 and DMSO as solvent. HRMS spectra were recorded by analysing a 50 ppm solution of the compound in a 6540 UHD Accurate-Mass Q-TOF LC/MS (Agilent Technologies) equipped with a Dual AJS ESI source. GC-MS spectra have been registered by using either an Agilent 7890B/7000C GC-MS-TQ or a GC-MS Shimadzu QP-2010 Instrument. Flash chromatography was performed by using silica gel (Merck, 0.040-0.063 mm) and mixtures of ethyl acetate and petroleum ether (fraction boiling in the range of 40-60 °C) in various ratios.
The QikProp program (QikProp, version 4.4, Schrodinger, LLC, New York, NY, 2015) was used to obtain the ADME properties of our compounds, and ATALUREN. It predicts both physically significant descriptors and pharmaceutically relevant features, such as principal descriptors and physiochemical properties. It also evaluated the drug-like acceptability of the compounds, based on Lipinski's rule of five, essential for rational drug design.
Molecular Design of the new molecules has been realized by a High Throughput Virtual Screening (HTVS) of an in-house library of about 30000 molecules (I. Pibiri, L. Lentini, R. Melfi, G. Gallucci, A. Pace, A. Spinello, G. Barone, A. Di Leonardo, Enhancement of premature stop codon readthrough in the CFTR gene by Ataluren (PTC124) derivatives, Eur . J. Med. Chem. 101 (2015) 236-244; Pibiri I., Lentini L., Tutone M. , Melfi R. , Pace A., Di Leonardo A. Exploring the readthrough of nonsense mutations by non-acidic Ataluren analogues selected by ligand-based virtual screening. , Eur. J. Med. Chem. 122 (2016) 429-435) .
The results disclosed in (Pibiri I., Lentini L., Tutone M. , Melfi R. , Pace A., Di Leonardo A. Exploring the readthrough of nonsense mutations by non-acidic Ataluren analogues selected by ligand-based virtual screening. Eur. J. Med. Chem. 122 (2016) 429-435) have been refined with 3D-QSAR (quantitative structure-activity relationships) pharmacophore modelling. The endpoint to build QSAR models was the luciferase activity known data. These values were converted to pFLUC (-log FLUC) values. In order to find the common pharmacophore hypothesis, we divided the 24 compounds in three different classes of activity related to the FLUC values (Pharm set) . We considered as active, compounds with FLUC values > 4.52 (ATALUREN FLUC value), as inactives, compounds with FLUC values £ 4.00, and as moderate actives, compounds with 4.39 £ FLUC values £ 4,51. Dataset was randomly split into a training set (19 compounds) for models generation, and test set (5 compounds) for the validation of developed models, as reported in Table 1. Table 1
Figure imgf000020_0001
Figure imgf000021_0001
In table 1 the compounds listed in the first column and labeled with the compounds named [1] are those disclosed in I. Pibiri, L. Lentini, M. Tutone, R. Melfi, A. Pace, A. Di Leonardo, "Exploring the readthrough of nonsense mutations by non-acidic Ataluren analogues selected by ligand-based virtual screening" Eur. J. Med. Chem. , 2016, 122, 429-435.
In table 1 the compounds listed in the first column and labeled with the compounds named [2] are those disclosed in I. Pibiri, L. Lentini, R. Melfi, G. Gallucci, A. Pace, A.
Spinello, G. Barone, A. Di Leonardo, "Enhancement of premature stop codon readthrough in the CFTR gene by Ataluren (PTC124) derivatives". Eur. J. Med. Chem., 2015, 101, 236-244.
In table 1 the compounds listed in the first column and labeled with the compounds named [3] are unpublished data.
Following Table 2 shows, wherein SD : standard deviation; F: Fisher test; P, significance level of variance ratio; RMSE: root mean square error. Table 2
Figure imgf000022_0001
Following Table 3 shows the predictive capability values of models .
Table 3
Figure imgf000022_0002
The models have been robustly validated, and Hypo.7 showed the best predictive capability, as showed in figure 1 and in Table 3.
Hypo .7 have been used as starting point to perform a new high- throughput virtual screening on an in-house database. From the top 5% of retrieved hits with the hypothesis, 58 Compounds have been prepared and tested. The synthesis has been realized by optimized synthetic protocols and the reactions have been monitored by TLC (Thin Layer Chromatography) . All the new synthesized compounds have been purified by column preparative chromatography performed with silica gel (Merck, 0.040-0.063 mm), by using mixtures of petroleum (fraction boiling in the range 40-60°C) and Ethyl acetate as eluent.
Further purification was realized by crystallization. All the synthesized compounds have been analysed by spectroscopic techniques such as 1H-NMR, 13C-NMR, UV, IR, GC-MS, to assess their molecular structure and their purity grade. The synthesis and characterization of compounds NV914 2 , 3 , 4 , 5 , 6-pentafluoro-N- ( 5- (perfluorophenyl ) -1, 2, 4-oxadiazol- 3-yl ) benzamide and NV930 ethyl 5-phenyl-l , 2 , 4-oxadiazole-3- carboxylate is reported.
The synthesis and crystal structure of NV848 ( 3-acetylamino-5- methyl-1 , 2 , 4-oxadiazole ) has been reported in the literature by some of the inventors of the present invention (N. Vivona, M. Ruccia, G. Cusmano, M. L. Marino, D. Spinelli, The thermally degenerate mononuclear rearrangement of 3- acetylamino-5-methyl-l , 2 , 4-oxadiazole, J . Heterocycl . Chem. 1975, 12, 1327-1328; A. Mugnoli, G. Barone, S. Buscemi,C. Z.
Lanza, A. Pace, M. Pani,D. Spinelli, On the structure of 3- acetylamino-5-methyl-l , 2 , 4-oxadiazole and on the fully degenerate rearrangements (FDR) of its anion: a stimulating comparison between the results of in-silicon chemistry' and laboratory chemistry', Journal of Physical Organic Chemistry (2009), 22(11), 1086-1093; A. Pace, I. Pibiri, A. Palumbo Piccionello, S. Buscemi,N. Vivona, G. Barone, Experimental and DFT Studies on Competitive Heterocyclic Rearrangements. Part 2:1 A One-Atom Side-Chain versus the Classic Three-Atom Side- Chain (Boulton-Katritzky) Ring Rearrangement of 3-Acylamino- 1 , 2 , 4-oxadiazoles , Journal of Organic Chemistry (2007), 72 (20) , 7656-7666. ) .
NV930, already reported in the literature, has been prepared by a different synthetic procedure: NV930 has been prepared by the classic amidoxime route: The amidoxime 1 (0.3 g) (prepared as reported in (P. S. Branco, S. Prabhakar, A. M. Lobo, D. J. Williams, "Reactions of hydroxylamines with ethyl cyanoformate . preparation of aminonitrones and their synthetic applications . "tetrahedron 1992, 48, 6335-6360)) was dissolved in 50 mL of toluene in a 250 mL round bottomed flask. Then, 1.2 eq. of the appropriate aroyl chloride and 1.2 eq. of pyridine were added and the reaction mixture was refluxed for 6-8 h monitoring the reaction by TLC until consumption of starting material. The solvent was removed under vacuum and water was added to the residue. Extraction with ethyl acetate and chromatographic separation on silica gel using mixtures of petroleum ether and ethyl acetate as eluent allowed to obtain the desired oxadiazole, further purified by crystallization.
Reaction Yield 80%, MP 50-52°C, from Ethanol. 1H NMR (300 MHz, CDC13 ) d : 8.22 (d, J = 7.2 Hz, 2H) , 7.64 (t, J = 7.4 Hz, 1H) , 7.55 (t, J = 7.4 Hz, 2H) , 4.55 (q, J = 7.1 Hz, 2H) , 1.47 (t, J = 7.1 Hz, 3H) . FT-IR cm-1, 1720. HRMS for C11H10N2O3 found 219.0699 [M+H]+ (Calcd. 219.0691) .
Figure imgf000024_0001
NV914 has been prepared by acylation with perfluorobenzoyl chloride of the amine 2, the latter reported in (Buscemi, Silvestre; Pace, Andrea; Pibiri, Ivana; Vivona, Nicolo; Caronna, Tullio, "Fluorinated heterocyclic compounds: an assay on the photochemistry of some fluorinated l-oxa-2-azoles : an expedient route to fluorinated heterocycles" Journal of
Fluorine Chemistry (2004), 125(2), 165-173, Buscemi,
Silvestre; Pace, Andrea; Frenna, Vincenzo; Vivona, Nicolo "A generalized synthesis of 3-amino-5-aryl-, 3-amino-5- polyfluorophenyl-, and 3-amino-5-alkyl-l , 2 , 4-oxadiazoles through ring-degenerate rearrangements" Heterocycles (2002),
57(5), 811-823; Buscemi, S.; Pace, A.; Calabrese, R. ; Vivona,
N.; Metrangolo, P." Fluorinated heterocyclic compounds. A photochemical synthesis of 3-amino-5-perfluoroaryl-1 , 2 , 4- oxadiazoles" Tetrahedron (2001), 57(27), 5865-5871). 1.2 eq. of perfluorobenzoyl chloride and 1.2 eq. of pyridine were added to the amine dissolved in toluene, and the reaction mixture was refluxed for 4 h monitoring the reaction by TLC until consumption of starting material. The solvent was removed under vacuum and water was added to the residue. Extraction with ethyl acetate and chromatographic separation on silica gel using mixtures of petroleum ether and ethyl acetate as eluent allowed to obtain the desired product, further purified by crystallization. Reaction Yield 90%, MP 208-210°C, from Ethanol. 1H NMR (300 MHz, CDC13 ) d : 9.09 (s, 1H) , FT-IR cm-1, 3290, 3180, 1750. HRMS for C15HF10N3O2 found 445.9917 [M+H]+ (Calcd. 445.9909).
Figure imgf000025_0001
Example 2 in vitro tests
To ascertain the effectiveness of the newly synthesized ataluren analogues in promoting the readthrough of premature termination codons was used the FLuc cell-based assay. To this aim HeLa cells were transfected transiently with the plasmids pFLuc-wild type (control) and pFLuc-opal (UGA stop mutation) (NIH Chemical Genomics Center, National Institutes of Health, Bethesda, USA) . FLuc gene expression was then measured by luminescence. HeLa cells transfected with the pFluc-wild type plasmid showed high levels of luciferase activity confirming the functioning of the assay. pFluc-opal cells did not show any activity but, after 24 hours from transfection, they were treated, for additional 24 hours, with ataluren and 58 different ataluren analogues all at the same concentration of 12mM. Following treatment a significant increase of luciferase activity, if compared to untreated, with: NV848, NV914, NV930 was observed as shown in figure 2. To work in a cell system containing exclusively nonsense mutations and in particular the more representative CFTR nonsense mutation, the G542X, FRT cells were engineered with a vector expressing nsCFTR (nonsense) . To this aim, Site Directed Mutagenesis of the full-length CFTR cDNA cloned in the pTracer-Zeocin (pTCF-wild type) vector (Gaslini Hospital Genova, Italy) was performed (CFTR DNA available at NCBI Reference Sequence: NG_016465.4 ) . To substitute the Glicine 542 coding codon GGA with a stop codon, was introduced a single nucleotide mutation. The first guanine of the codon, position 1624 of the cDNA, was changed in a thymine to introduce an opal nonsense mutation. We amplified the plasmid harbouring cDNA with the following primers :
SEQ ID NO. 1: 5 ' -tgattccaccttctcaaagaactatattgtctttctctgcaaac-3 ' gl624tup (reverse)
SEQ ID NO. 2:
5 ' -gtttgcagagaaagacaatatagttctttgagaaggtggaatca-3 ' gl 624tdw ( forward) Treatment with Dpnl restriction enzyme (target: 5'Gm6ATC3') removed methylated parental DNA (isolated from dam+ E. coli) . Newly synthesized plasmids were transformed into XLl-Blue competent cells. We obtained 11 colonies, all confirmed to bring the pTracer-CFTR plasmid by colony PCR performed with two primers perfectly annealing to the template at 52 °C: SEQ ID NO. 3: 5 ' -ctaatgagaaacggtgtaag-3 ' CFTRup2 reverse primer and : SEQ ID NO. 4: 5' -ggtgattatgggagaactgg-3' CFTRdwl forward primer, as shown in figure 3. clonel was selected for further characterization by "selective PCR". A forward primer SEQ. ID NO. 5 5'- gagaaagacaatatagttcttt-3' CFTR1624opaldw, with 3' termini matching only to mutant nucleotide allows amplification of the corresponding mutant target DNA and not of wild type DNA, when the right selective PCR conditions are used. We performed reactions with a thermostable DNA polymerase lacking 3' to 5' proofreading activity (DyNAzyme™ II DNA Polymerase) , identical amount of purified plasmid DNA, either wild type or mutagenized, and the reverse primer SEQ. ID. NO. 3: 5' ctaatgagaaacggtgtaag 3' CFTRup2.
To distinguish between mutant and wild type DNA, was used a gradient thermocycler and the following primer annealing temperatures: 44, 46, 48, 50 and 52 °C. Positive controls (C+) were included where the same DNAs were amplified with the CFTRup2 /CFTRdwl primers (annealing T 52°C) .
A DNA fragment of the correct size was amplified where expected, either in clone-1 or wild type DNA and in positive controls, as shown in figure4.
In the case of Clonel when the selective forward primer was used, the amplification efficiency was the same at any annealing T. In the case of wild type DNA, amplification product amount decreased as the T raised, until it became almost undetectable at 52 °C, thus suggesting that Clonel was positive to mutagenesis. Successful mutagenesis was finally confirmed by sequencing (BRM genomics, Padova, Italy) .
To further evaluate the efficacy of NV914, NV848, NV930 , FRT cells were transfected with the pTRACER vectors containing either the wild type CFTR or the nsCFTR (G542X-opal) cDNA and selected by Zeocin resistance. The advantage of the use of these cells is that they don't express cAMP dependent channels (as CFTR) or CFTR protein. The expression of the human CFTR wild type and nsCFTR (G542X-opal ) in transfected FRT cells was evaluated by qRT-PCR and Western blot, as shown in figure 5.
The same FRT cells were then treated with NV914, NV848, NV930 (12mM), and ATALUREN (12 m M) (as positive control) for 24 hours and the expression of the human CFTR wild type and nsCFTR (G542X-opal ) was again evaluated by immunofluorescence analysis. Immunofluorescence microscopy images allow to visualize CFTR localization at the cell membrane suggesting the occurrence of translation readthrough and proper localization also in this cell type after treatment.
The results showed that the exposition of nsCFTR (G542X-opal ) FRT cells to the compounds induced the CFTR full-length expression and membrane localization, in particular for compounds NV930 and NV914.
HeLa cells were used to determine the possible cytotoxic effects of our compounds and the impact on cell proliferation. In figure 7 are reported the percentages of dead cells and proliferating cells after treatment with 12mM compounds and 12mM ATALUREN. The results showed that the compounds and ATALUREN induce alight increase in dead cells at 24h (ATALUREN: 4%; NV848:7; NV914: 5; NV930 : 2) and 72h (ATALUREN: 7%; NV848:6; NV914: 2; NV930 : 4 that was constant in the time. Was observed that HeLa cells proliferate as untreated cells when treated daily (every 24h) for 10 days with our compounds.
In the attempt to predict absorption, distribution, metabolism, and excretion (ADME) for the compounds, these was submitted to Qikprop calculations.
Regarding ADME predictions the final result is expressed in terms of Istars, Number of property or descriptor values that fall outside the 95% range of similar values for known drugs large number of stars suggests that a molecule is less drug like than molecules with few stars. The following properties and descriptors are included in the determination of Istars: MW, dipole, IP, EA, SASA, FOSA, FISA, PISA, WPSA, PSA, volume, #rotor, donorHB, accptHB, glob, QPpolrz, QPlogPC16, QPlogPoct, QPlogPw, QPlogPo/w, logS , QPLogKhsa, QPlogBB, #metabol, as shown in the following Table 4 wherein all the calculated values for the compounds were compared with the calculated values for ataluren. Table 4
Figure imgf000029_0001
In table 4 MW, molecular weight; IP, PM3 calculated ionization potential (negative of HOMO energy) ; EA, PM3 calculated 5 electron affinity (negative of LUMO energy) ; SASA, Total solvent accessible surface area (SASA) in square angstroms using a probe with a 1.4 A radius; FOSA, Hydrophobic component of the SASA (saturated carbon and attached hydrogen); FISA, Hydrophilic component of the SASA (SASA on N, 0, H on 10 heteroatoms, carbonyl C) ; PISA, (carbon and attached hydrogen) component of the SASA; WPSA, Weakly polar component of the SASA (halogens, P, and S) ; Volume, Total solvent- accessible volume in cubic angstroms using a probe with a 1.4 A radius; #rotor, number of rotatable bonds; donorHB, number 15 of h-bond donor, accptHB, number of H-bond acceptor; glob,
Globularity descriptor, (4nr2) v (SASA) , where r is the radius of a sphere with a volume equal to the molecular volume; QPpolrz, Predicted polarizability in cubic angstroms, QPlogPC16, Predicted hexadecane/gas partition coefficient; QPlogPoct, Predicted octanol/gas partition coefficient ;
QPlogPw, Predicted water/gas partition coefficient; QPlogPo/w, Predicted octanol/water partition coefficient.; QPlogKhsa, Prediction of binding to human serum albumin; QPlogBB, Predicted brain/blood partition coefficient; #metab, Number of likely metabolic reactions.
Furthermore, the compounds respect the Lipinski's rule of five, and they have a predicted human oral absorption between 70 and 100%.
It was also evaluated the production of FRT cells expressing nonsense-CFTR (nsCFTR) and the CFTR expression and functionality after treatment with NV848, NV914 and NV930.
FRT cells transfected with a pTracer nsCFTR-G542X-opal vector the treated with NV848, NV914, NV930 (12mM), and ATALUREN (12 m M) as positive control, for 24 hours and the expression of the human CFTR wild type and nsCFTR (nsCFTR-G542X-opal) was evaluated by immunofluorescence analysis.
In details, immunofluorescence analysis was used to detect the CFTR protein following the readthrough of the UGA stop codon in nsCFTR (opal) FRT cells untreated, treated with G418 as positive contro) and with PTC124 and NV848, Nv914, NV930 for
24 h. CFTR protein was revealed by a specific antibody targeting its first external portion and a secondary antibody (SC2092-red) . Nuclei (blue) were DAPI stained.
Immunofluorescence microscopy images allowed to visualize CFTR localization at the cell membrane suggesting the occurrence of translation readthrough and proper localization also in this cell type after treatment, and the results showed that the exposition of nsCFTR (G542X-opal) FRT cells to the NV848, NV914, NV930 compounds induced the CFTR full-length expression and membrane localization.
Moreover, by Western blot analysis was detected the amount of CFTR protein after translation readthrough in nsCFTR (G542X- opal) FRT cells treated with NV848, NV914, NV930 (12mM) . In details, Western blot analysis was used to detect CFTR protein in bronco-epithelial BE (cells and in transfected FRT cells (FRT-CFTR (gG542X-opal ) untreated and treated with PTC124 and and NV848, NV914, NV930, for 24 hours and b-tubulin was used as control for the protein loading.
To ascertain the functionality of the re-expressed CFTR protein, produced after exposure to the compounds, a quench- EYFP assay was performed. This assay is based on iodide- mediated quenching rates of an ectopically expressed mutant form of the Yellow fluorescent protein (YFP) . To this aim, nsCFTR (G542X-opal ) FRT-cells were transfected with the plasmid pCDNA3.1 EYFP (M148Q; I152L) and selected for the resistance to the G418 antibiotic. Cells were plated in a 6 well plate one day before the experiment, they were stimulated with forskolin (20 mM) for 20 min and placed in a buffer containing iodide (PBSlx similar buffer, NaCl is replaced by equimolars of Nal) . Changes in fluorescence intensity were monitored by a Zeiss fluorescence microscope and the images were recorded every 1.5 s with a CCD digital camera (AxioCam, Zeiss) . The same analysis was performed by measuring the changes in fluorescence intensity by a fluorimeter confirming the activity of the CFTR channel in these cells.
FRT cells were also engineered with a vector expressing nsCFTR (nonsense) . To this aim, Site 15 Directed Mutagenesis of the full-length CFTR cDNA cloned in the pTracer Zeocin (pTCF-wild type) vector (provided by Gaslini Hospital Genova, Italy) was performed, the CFTR DNA is available at NCBI Reference Sequence NG_016465.4. With the aim of introducing in the CFTR cDNA single base mutations cl654t or cl657t to convert, respectively, Glycin 552 (caa>taa ochre) or Arginine 553 (cga>tga opal) in nonsense codons, site-directed mutagenesis of the full-length cDNA cloned in the pTracer Zeocin (pTCF- wild type) vector (provided by Gaslini Hospital Genova, Italy) was performed (CFTR DNA available at NCBI Reference Sequence: NG_016465.4) . The pTCF-wild type vector was amplified by PCR with the following primers:
Q552X och dw forward, SEQ.ID No. 6 gaatcacactgagtggaggttaacgagcaagaatttcttta
Q552X och up reverse SEQ.ID No. 7 taaagaaattcttgctcgttaacctccactcagtgtgattc or
R553X op dw forward, SEQ.ID No. 8 aatcacactgagtggaggtcaatgagcaagaatttctttag R553X op up reverse SEQ.ID No. 9 ctaaagaaattcttgctcattgacctccactcagtgtgatt
Treatment with Dpnl restriction enzyme (target: 5'Gm6ATC3') removed methylated parental DNA (isolated from dam+ E. coli) . Newly synthesized plasmids were transformed into XLl-Blue competent cells. We obtained 11 colonies from Q552X reaction and 12 from R553X. All were confirmed to bring the pTracer- CFTR plasmid by colony PCR, performed with two primers perfectly annealing to the template at 56°C:
CFTRup2 reverse primer SEQ.ID No. 10
Ctaatgagaaacggtgtaag and CFTRdwl forward primer SEQ.ID No. 11 ggtgattatgggagaactgg
Q552X clone 1 and R553X clone 18 were selected for further characterization by selective PCR, based on the use of the CFTRup2 reverse primer SEQ.ID No. 9 paired with the following selective forward primers : cl654tdw for Q552X SEQ.ID No. 12 aatcacactgagtggaggtt or cl657tdw for R553X SEQ.ID No. 13 cacactgagtggaggtcaat
They harbor a 3' termini matching only to mutant nucleotides, which allow the amplification of the mutant target DNA and not of wt DNA by a thermostable DNA polymerase lacking 3' to 5' proofreading activity (DyNAzyme™ II DNA Polymerase) . Primer annealing temperatures ranging from 48 to 56 °C were used. Amplification efficiency, of mutant clones 1 and 18 was the same at any annealing T (Ta) while in the case of wt template DNA, it decreased as the Ta raised (380 bp amplicon became almost undetectable at 56°C) . This suggested that both clones were positive to mutagenesis. A DNA fragment of 608bp was amplified in positive controls, as expected. Successful mutagenesis was confirmed by sequencing (BRM genomics) :
To further evaluate the efficacy of NV848, NV914 and NV930 FRT cells were transfected with the pTracer vectors containing either the WT-CFTR (CFTRWT ) or the R553X-CFTR and the Q552X- CFTR (nsCFTR- R553X-opal, nsCFTR-Q552X ochre) human cDNA and selected by Zeocin resistance. The expression of the CFTRWT and nsCFTR CFTR (nsCFTR- R553X-opal, nsCFTR-Q552X ochre) in transfected FRT cells was evaluated by qRT-PCR. The nsCFTR- Q552X ochre, nsCFTR- R553X-opal FRT transfected cells were treated with NV848, (12mM) , and ATALUREN (12 m M) as positive control, for 24 hours and the expression of the human CFTR was evaluated by immunofluorescence analysis. Immunofluorescence microscopy images showed that the exposition of the nsCFTR- R553X-opal, nsCFTR-Q552X ochre FRT cells to the NV848, NV914, NV930 compounds induced the CFTR full-length expression and membrane localization.

Claims

1. 2 , 3 , 4 , 5 , 6-pentafluoro-N- ( 5- (perfluorophenyl ) -1 , 2 , 4- oxadiazol-3-yl ) benzamide .
2. Method for the preparation of 2, 3, 4, 5, 6-pentafluoro-N- ( 5- (perfluorophenyl ) -1 , 2 , 4-oxadiazol-3-yl ) benzamide by acylation with perfluorobenzoyl chloride of amine 2 according to the following reaction
Figure imgf000035_0001
3. Pharmaceutical composition comprising a pharmacologically effective amount of 2, 3, 4,5,6- pentafluoro-N- (5- (perfluorophenyl ) -1,2, 4-oxadiazol-3- yl) benzamide or its prodrug and pharmaceutically acceptable excipients.
4. 2 , 3 , 4 , 5 , 6-pentafluoro-N- ( 5- (perfluorophenyl ) -1 , 2 , 4- oxadiazol-3-yl ) benzamide for use as a medicament.
5. 2 , 3 , 4 , 5 , 6-pentafluoro-N- ( 5- (perfluorophenyl ) -1 , 2 , 4- oxadiazol-3-yl ) benzamide for use for the treatment of diseases caused by nonsense mutations.
6. N- ( 5-methyl-l , 2 , 4-oxadiazol-3-yl ) acetamide for use as a medicament .
7. N- ( 5-methyl-l , 2 , 4-oxadiazol-3-yl ) acetamide for use in the treatment of diseases caused by nonsense mutation.
8. Compounds of formula (I)
Figure imgf000036_0001
Wherein
R1 is selected from the group consisting of: alkyl amide, polyfluoroalkyl-amide, aryl amide, polyfluoroaryl amide, polyfluoroaryl ester.
R2 is selected from the group consisting of: alkyl, polyfluoroalkyl, aryl, polyfluoroaryl for use in the treatment of diseases caused by nonsense mutations .
9. Pharmaceutical composition comprising a pharmacologically effective amount of at least one compound of formula (I) of claim from 8 or its prodrug or mixture thereof and pharmaceutically acceptable excipients, for use in the treatment of diseases caused by nonsense mutations.
10. Method of preparation of ethyl 5-phenyl-l , 2 , 4- oxadiazole-3-carboxylate according to the following reaction
Figure imgf000036_0002
PCT/EP2018/081850 2017-11-23 2018-11-20 Oxadiazole derivatives for the treatment of genetic diseases due to nonsense mutations WO2019101709A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP18807926.3A EP3713934B1 (en) 2017-11-23 2018-11-20 Oxadiazole derivatives for the treatment of genetic diseases due to nonsense mutations
US16/770,240 US11203578B2 (en) 2017-11-23 2018-11-20 Oxadiazole derivatives for the treatment of genetic diseases due to nonsense mutations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT201700134511 2017-11-23
IT102017000134511 2017-11-23

Publications (1)

Publication Number Publication Date
WO2019101709A1 true WO2019101709A1 (en) 2019-05-31

Family

ID=61527402

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2018/081850 WO2019101709A1 (en) 2017-11-23 2018-11-20 Oxadiazole derivatives for the treatment of genetic diseases due to nonsense mutations

Country Status (3)

Country Link
US (1) US11203578B2 (en)
EP (1) EP3713934B1 (en)
WO (1) WO2019101709A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023235384A1 (en) * 2022-06-01 2023-12-07 Sanofi Us Services Inc. Compounds for enhancing read through of genes containing premature termination codons and methods for making and using the same
US11938134B2 (en) 2017-03-10 2024-03-26 Eikonizo Therapeutics, Inc. Metalloenzyme inhibitor compounds

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006044502A2 (en) 2004-10-13 2006-04-27 Ptc Therapeutics, Inc. Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases
WO2006110483A1 (en) 2005-04-08 2006-10-19 Ptc Therapeutics, Inc. Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
WO2008045566A1 (en) 2006-10-12 2008-04-17 Ptc Therapeutics, Inc. Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
WO2008130370A1 (en) 2006-09-25 2008-10-30 Ptc Therapeutics, Inc. Hydroxylated 1,2,4-oxadiazole benzoic acid compounds, compositions thereof and the use for nonsense suppression
WO2011072281A1 (en) 2009-12-11 2011-06-16 Ptc Therapeutics, Inc. Methods for treating methylmalonic acidemia
WO2014085490A1 (en) 2012-11-29 2014-06-05 Chemocentryx, Inc. Cxcr7 antagonists
WO2015134711A1 (en) 2014-03-06 2015-09-11 Ptc Therapeutics, Inc. Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid
WO2015188037A1 (en) 2014-06-06 2015-12-10 Ptc Therapeutics, Inc. Methods of treatment using a 1,2,4-oxadiazole benzoic acid

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170204073A1 (en) 2004-10-13 2017-07-20 Ptc Therapeutics, Inc. Compounds for nonsense suppression, and methods for their use
WO2006044456A1 (en) 2004-10-13 2006-04-27 Ptc Therapeutics, Inc. Compounds for nonsense suppression, and methods for their use
WO2006044682A1 (en) 2004-10-13 2006-04-27 Ptc Therapeutics, Inc. Compounds for nonsense suppression, and methods for their use
WO2006044503A2 (en) 2004-10-13 2006-04-27 Ptc Therapeutics, Inc. Compounds for nonsense suppression, use of these compounds for the manufacture of a medicament for treating somatic mutation-related diseases
WO2006044505A2 (en) 2004-10-13 2006-04-27 Ptc Therapeutics, Inc. Compounds for nonsense suppression, and methods for their use
WO2006044502A2 (en) 2004-10-13 2006-04-27 Ptc Therapeutics, Inc. Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases
WO2006110483A1 (en) 2005-04-08 2006-10-19 Ptc Therapeutics, Inc. Compositions of an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
WO2008130370A1 (en) 2006-09-25 2008-10-30 Ptc Therapeutics, Inc. Hydroxylated 1,2,4-oxadiazole benzoic acid compounds, compositions thereof and the use for nonsense suppression
WO2008045566A1 (en) 2006-10-12 2008-04-17 Ptc Therapeutics, Inc. Methods for dosing an orally active 1,2,4-oxadiazole for nonsense mutation suppression therapy
WO2011072281A1 (en) 2009-12-11 2011-06-16 Ptc Therapeutics, Inc. Methods for treating methylmalonic acidemia
WO2014085490A1 (en) 2012-11-29 2014-06-05 Chemocentryx, Inc. Cxcr7 antagonists
WO2015134711A1 (en) 2014-03-06 2015-09-11 Ptc Therapeutics, Inc. Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid
WO2015188037A1 (en) 2014-06-06 2015-12-10 Ptc Therapeutics, Inc. Methods of treatment using a 1,2,4-oxadiazole benzoic acid

Non-Patent Citations (37)

* Cited by examiner, † Cited by third party
Title
A. MUGNOLI; G. BARONE; S. BUSCEMI; C. Z. LANZA; A. PACE; M. PANI; D. SPINELLI: "On the structure of 3-acetylamino-5-methyl-l,2,4-oxadiazole and on the fully degenerate rearrangements (FDR) of its anion: a stimulating comparison between the results of in-silicon chemistry' and laboratory chemistry", JOURNAL OF PHYSICAL ORGANIC CHEMISTRY, vol. 22, no. 11, 2009, pages 1086 - 1093
A. PACE; I. PIBIRI; A. PALUMBO PICCIONELLO; S. BUSCEMI; N. VIVONA; G. BARONE: "Experimental and DFT Studies on Competitive Heterocyclic Rearrangements. Part 2:1 A One-Atom Side-Chain versus the Classic Three-Atom Side-Chain (Boulton-Katritzky) Ring Rearrangement of 3-Acylamino-1,2,4-oxadiazoles", JOURNAL OF ORGANIC CHEMISTRY, vol. 72, no. 20, 2007, pages 7656 - 7666
A. PRAYLE; A.R. SMYTH: "Aminoglycoside use in cystic fibrosis: therapeutic strategies and toxicity", CURR. OPIN. PULM. MED., vol. 16, 2010, pages 604 - 610
ALMERICO, A.M.; TUTONE, M.; LAURIA, A.: "3D-QSAR pharmacophore modeling and in silico screening of new Bcl-xl inhibitors", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 45, no. 11, 2010, pages 4774 - 4782, XP027408885
ALMERICO, A.M.; TUTONE, M.; LAURIA, A.: "Receptor-guided 3D-QSAR approach for the discovery of c-kit tyrosine kinase inhibitors", JOURNAL OF MOLECULAR MODELING, vol. 18, no. 7, 2012, pages 2885 - 2895, XP035075599, DOI: doi:10.1007/s00894-011-1304-0
ALMERICO, A.M.; TUTONE, M.; PANTANO, L.; LAURIA, A.: "A3 adenosine receptor: Homology modeling and 3D-QSAR studies", JOURNAL OF MOLECULAR GRAPHICS AND MODELLING, vol. 42, 2013, pages 60 - 72, XP028535807, DOI: doi:10.1016/j.jmgm.2013.03.001
BUSCEMI, S.; PACE, A.; CALABRESE, R.; VIVONA, N.; METRANGOLO, P.: "Fluorinated heterocyclic compounds. A photochemical synthesis of 3-amino-5-perfluoroaryl-1,2,4-oxadiazoles", TETRAHEDRON, vol. 57, no. 27, 2001, pages 5865 - 5871, XP004254898, DOI: doi:10.1016/S0040-4020(01)00524-5
BUSCEMI, SILVESTRE; PACE, ANDREA; FRENNA, VINCENZO; VIVONA, NICOLO: "A generalized synthesis of 3-amino-5-aryl-, 3-amino-5-polyfluorophenyl-, and 3-amino-5-alkyl-l,2,4-oxadiazoles through ring-degenerate rearrangements", HETEROCYCLES, vol. 57, no. 5, 2002, pages 811 - 823
BUSCEMI, SILVESTRE; PACE, ANDREA; PIBIRI, IVANA; VIVONA, NICOLO; CARONNA, TULLIO: "Fluorinated heterocyclic compounds: an assay on the photochemistry of some fluorinated 1-oxa-2-azoles: an expedient route to fluorinated heterocycles", JOURNAL OF FLUORINE CHEMISTRY, vol. 125, no. 2, 2004, pages 165 - 173, XP004486519, DOI: doi:10.1016/j.jfluchem.2003.07.006
DIXON, S. L.; SMONDYREV, A. M.; KNOLL, E. H.; RAO, S. N.; SHAW, D. E.; FRIESNER, R. A.: "PHASE: A New Engine for Pharmacophore Perception, 3D QSAR Model Development, and 3D Database Screening. 1. Methodology and Preliminary Results", J. COMPUT. AIDED MOL. DES., vol. 20, 2006, pages 647 - 671, XP019465878, DOI: doi:10.1007/s10822-006-9087-6
E.M. WELCH; E.R. BARTON; J. ZHUO; Y. TOMIZAWA; W.J. FRIESEN; P. TRIFILLIS; S. PAUSHKIN; M. PATEL; C.R. TROTTA; S. HWANG: "PTC124 targets genetic disorders caused by nonsense mutations", NATURE, vol. 447, 2007, pages 87 - 91, XP009096628, DOI: doi:10.1038/nature05756
GOLDMANN, T.; OVERLACK, N.; MOLLER, F.; BELAKHOV, V.; VAN WYK, M.; BAASOV, T.; WOLFRUM, U.; NAGEL-WOLFRUM, K.: "A comparative evaluation of NB30, NB54 and PTC124 in translational read-through efficacy for treatment of an USH1C nonsense mutation", EMBO MOL MED, vol. 4, no. 11, 2012, pages 1186 - 99
HARMER, S. C.; MOHAL, J. S.; KEMP, D.; TINKER, A.: "Readthrough of long-QT syndrome type 1 nonsense mutations rescues function but alters the biophysical properties of the channel", BIOCHEM J, vol. 443, no. 3, 2012, pages 635 - 42
I. PIBIRI; L. LENTINI; M. TUTONE; R. MELFI; A. PACE; A. DI LEONARDO: "Exploring the readthrough of nonsense mutations by non-acidic Ataluren analogues selected by ligand-based virtual screening", EUR. J. MED. CHEM., vol. 122, 2016, pages 429 - 435, XP029705949, DOI: doi:10.1016/j.ejmech.2016.06.048
I. PIBIRI; L. LENTINI; R. MELFI; G. GALLUCCI; A. PACE; A. SPINELLO; G. BARONE; A. DI LEONARDO: "Enhancement of premature stop codon readthrough in the CFTR gene by Ataluren (PTC124) derivatives", EUR. J. MED. CHEM., vol. 101, 2015, pages 236 - 244, XP029258961, DOI: doi:10.1016/j.ejmech.2015.06.038
J. KARIJOLICH; Y.T. YU: "Therapeutic suppression of premature termination codons: mechanisms and clinical considerations (Review", INT. J. MOL. MED., vol. 34, 2014, pages 355 - 362, XP055370036, DOI: doi:10.3892/ijmm.2014.1809
J.T. MENDELL; H.C. DIEZ: "When the message goes awry: disease-producing mutations that influence mRNA content and performance", CELL, vol. 107, 2001, pages 411 - 414
JOHANNA SENGER ET AL: "Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors", JOURNAL OF MEDICINAL CHEMISTRY, vol. 59, no. 4, 22 December 2015 (2015-12-22), pages 1545 - 1555, XP055497385, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.5b01493 *
KEREM E; HIRAWAT S; ARMONI S; YAAKOV Y; SHOSEYOV D; COHEN M; NISSIM-RAFINIA M; BLAU H; RIVLIN J; AVIRAM M: "Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial.", LANCET, vol. 372, no. 9640, 30 August 2008 (2008-08-30), pages 719 - 27, XP024520939, DOI: doi:10.1016/S0140-6736(08)61168-X
L. BIDOU; V. ALLAMAND; J.P. ROUSSET; 0. NAMY: "Sense from nonsense: therapies for premature stop codon diseases", TRENDS MOL. MED., vol. 18, 2012, pages 679 - 688, XP055105348, DOI: doi:10.1016/j.molmed.2012.09.008
L. LENTINI; R. MELFI; A. DI LEONARDO; A. SPINELLO; G. BARONE; A. PACE; A. PALUMBO PICCIONELLO; I. PIBIRI: "Towards a rationale for the PTC124 (Ataluren) promoted read-through of premature stop codons: a computational approach and GFP reporter cell-based assay", MOL. PHARM., vol. 11, 2014, pages 653 - 664
L.S. MC COY; Y. XIE; Y. TOR: "Antibiotics that target protein synthesis", WILEY INTERDISCIP. REV. RNA, vol. 2, 2011, pages 209 - 232
LAURIA, A.; IPPOLITO, M.; FAZZARI, M.; TUTONE, M.; DI BLASI, F.; MINGOIA, F.; ALMERICO, A.M.: "IKK-β inhibitors: An analysis of drug-receptor interaction by using Molecular Docking and Pharmacophore 3D-QSAR approaches", JOURNAL OF MOLECULAR GRAPHICS AND MODELLING, vol. 29, no. 1, 2010, pages 72 - 81, XP027216001
MCELROY, S. P.; NOMURA, T.; TORRIE, L. S.; WARBRICK, E.; GARTNER,U.; WOOD, G.; MCLEAN, W. H.: "A lack of premature termination codon read-through efficacy of PTC124 (Ataluren) in a diverse array of reporter assays", PLOS BIOL, vol. 11, no. 6, 2013, pages elO01593
N. VIVONA; M. RUCCIA; G. CUSMANO; M. L. MARINO; D. SPINELLI: "The thermally degenerate mononuclear rearrangement of 3-acetylamino-5-methyl-l,2,4-oxadiazole", J.HETEROCYCL. CHEM., vol. 12, 1975, pages 1327 - 1328
P. S. BRANCO; S. PRABHAKAR; A. M. LOBO; D. J. WILLIAMS: "Reactions of hydroxylamines with ethyl cyanoformate. preparation of aminonitrones and their synthetic applications", TETRAHEDRON, vol. 48, 1992, pages 6335 - 6360
PERRICONE, U.; WIEDER, M.; SEIDEL, T.; LANGER, T.; PADOVA, A.; ALMERICO, A.M.; TUTONE, M.: "A Molecular Dynamics-Shared Pharmacophore Approach to Boost Early-Enrichment Virtual Screening: A Case Study on Peroxisome Proliferator-Activated Receptora", CHEMMEDCHEM, vol. 12, 2017, pages 1399 - 1407
PIBIRI I.; LENTINI L.; TUTONE M.; MELFI R.; PACE A.; DI LEONARDO A: "Exploring the readthrough of nonsense mutations by non-acidic Ataluren analogues selected by ligand-based virtual screening", EUR. J. MED. CHEM., vol. 122, 2016, pages 429 - 435, XP029705949, DOI: doi:10.1016/j.ejmech.2016.06.048
PIBIRI, I.; LENTINI, L.; TUTONE, M.; MELFI, R.; PACE, A.; DI LEONARDO, A.: "Exploring the readthrough of nonsense mutations by non-acidic Ataluren analogues selected by ligand-based virtual screening", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 122, 2016, pages 429 - 435, XP029705949, DOI: doi:10.1016/j.ejmech.2016.06.048
S.M. ROWE; J.P. CLANCY: "Pharmaceuticals targeting nonsense mutations in genetic diseases", BIODRUGS, vol. 23, 2009, pages 165 - 174, XP009501764, DOI: doi:10.2165/00063030-200923030-00003
SARKAR, C.; ZHANG, Z.; MUKHERJEE, A. B.: "Stop codon read-through with PTC124 induces palmitoyl-protein thioesterase-1 activity, reduces thioester load and suppresses apoptosis in cultured cells from INCL patients", MOL GENET METAB, vol. 104, no. 3, 2011, pages 338 - 45, XP028328997, DOI: doi:10.1016/j.ymgme.2011.05.021
SENGER J. ET AL.: "Synthesys and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors", J. MED. CHEM, vol. 59, no. 4, 2015, pages 1545 - 1555, XP055497385, DOI: doi:10.1021/acs.jmedchem.5b01493
SERMET-GAUDELUS I; BOECK KD; CASIMIR GJ; VERMEULEN F; LEAL T; MOGENET A; ROUSSEL D; FRITSCH J; HANSSENS L; HIRAWAT S: "Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis", AM J RESPIR CRIT CARE MED, vol. 182, no. 10, 15 November 2010 (2010-11-15), pages 1262 - 72
SERMET-GAUDELUS I; BOECK KD; CASIMIR GJ; VERMEULEN F; LEAL T; MOGENET A; ROUSSEL D; FRITSCH J; HANSSENS L; HIRAWAT S: "Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis", AM J RESPIRCRIT CARE MED, vol. 182, no. 10, 15 November 2010 (2010-11-15), pages 1262 - 72
T. GOLDMANN; N. OVERLACK; F. MOLLER; V. BELAKHOV; M. VAN WYK; T. BAASOV; U. WOLFRUM; K. NAGEL-WOLFRUM: "A comparative evaluation of NB30, NB54 and PTC124 in translational read-through efficacy for treatment of an USH1C nonsense mutation", EMBO MOL. MED., vol. 4, 2012, pages 1186 - 1199
TUTONE, M.; PANTANO, L.; LAURIA, A.; ALMERICO, A.M.: "Molecular dynamics, dynamic site mapping, and highthroughput virtual screening on leptin and the Ob receptor as anti-obesity target", JOURNAL OF MOLECULAR MODELING, vol. 20, no. 5, 2014, XP035307006, DOI: doi:10.1007/s00894-014-2247-z
V. MALIK; L.R. RODINO-KLAPAC; L. VIOLLET; J.R. MENDELL: "Aminoglycoside-induced mutation suppression (stop codon read- through) as a therapeutic strategy for Duchenne muscular dystrophy", THER. ADV. NEUROL. DISORD., vol. 3, 2010, pages 379 - 389

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11938134B2 (en) 2017-03-10 2024-03-26 Eikonizo Therapeutics, Inc. Metalloenzyme inhibitor compounds
WO2023235384A1 (en) * 2022-06-01 2023-12-07 Sanofi Us Services Inc. Compounds for enhancing read through of genes containing premature termination codons and methods for making and using the same

Also Published As

Publication number Publication date
EP3713934B1 (en) 2022-04-13
EP3713934A1 (en) 2020-09-30
US11203578B2 (en) 2021-12-21
US20210002238A1 (en) 2021-01-07

Similar Documents

Publication Publication Date Title
Lentini et al. Toward a rationale for the PTC124 (Ataluren) promoted readthrough of premature stop codons: a computational approach and GFP-reporter cell-based assay
Shen et al. Structural and in vivo characterization of Tubastatin A, a widely used histone deacetylase 6 inhibitor
Senger et al. Synthesis and biological investigation of oxazole hydroxamates as highly selective histone deacetylase 6 (HDAC6) inhibitors
Shen et al. Bicyclic-capped histone deacetylase 6 inhibitors with improved activity in a model of axonal Charcot–Marie–Tooth disease
Lin et al. Design and synthesis of orally bioavailable aminopyrrolidinone histone deacetylase 6 inhibitors
Chancellor et al. Discovery of 2-arylbenzoxazoles as upregulators of utrophin production for the treatment of Duchenne muscular dystrophy
Löber et al. Recent advances in the search for D3-and D4-selective drugs: probes, models and candidates
Simoni et al. Combining galantamine and memantine in multitargeted, new chemical entities potentially useful in Alzheimer’s disease
Toledo-Sherman et al. Development of a series of aryl pyrimidine kynurenine monooxygenase inhibitors as potential therapeutic agents for the treatment of Huntington’s disease
Pibiri et al. Exploring the readthrough of nonsense mutations by non-acidic Ataluren analogues selected by ligand-based virtual screening
Pibiri et al. Enhancement of premature stop codon readthrough in the CFTR gene by Ataluren (PTC124) derivatives
Tutone et al. Deciphering the nonsense readthrough mechanism of action of ataluren: an in silico compared study
Pibiri et al. Rescuing the CFTR protein function: Introducing 1, 3, 4-oxadiazoles as translational readthrough inducing drugs
Szychowski et al. Discovery of an orally bioavailable and selective PKMYT1 inhibitor, RP-6306
Carta et al. 3-Aryl-2-[1H-benzotriazol-1-yl] acrylonitriles: A novel class of potent tubulin inhibitors
Lee Walmsley et al. Fragment-derived selective inhibitors of dual-specificity kinases DYRK1A and DYRK1B
US20220313628A1 (en) Methods for selecting phosphatase selective and non-selective phosphatase inhibitors
Furlotti et al. Hit optimization of 5-substituted-N-(piperidin-4-ylmethyl)-1 H-indazole-3-carboxamides: Potent glycogen synthase kinase-3 (GSK-3) inhibitors with in vivo activity in model of mood disorders
Sahu et al. A recent review on drug modification using 1, 2, 3-triazole
Sugane et al. Atropisomeric 4-phenyl-4 H-1, 2, 4-triazoles as selective glycine transporter 1 inhibitors
Macabuag et al. Developing HDAC4-selective protein degraders to investigate the role of HDAC4 in Huntington’s disease pathology
US20150374737A1 (en) Dual-Action Compounds Targeting Adenosine A2A Receptor and Adenosine Transporter for Prevention and Treatment of Neurodegenerative Diseases
EP3713934B1 (en) Oxadiazole derivatives for the treatment of genetic diseases due to nonsense mutations
Tutone et al. Pharmacophore-based design of new chemical scaffolds as translational readthrough-inducing drugs (TRIDs)
Liu et al. Crystallography-Guided Optimizations of the Keap1–Nrf2 Inhibitors on the Solvent Exposed Region: From Symmetric to Asymmetric Naphthalenesulfonamides

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18807926

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018807926

Country of ref document: EP

Effective date: 20200623